1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Orally Inhaled Bronchodilators to 2022

Orally Inhaled Bronchodilators to 2022

  • April 2015
  • -
  • Greystone Research Associates

Asthma and COPD continue to be a health segments that present significant challenges to patients and the caregiver community. Patient adherence with prescribing instructions and treatment protocols remains sub-optimal across all patient categories, but particularly for the young and the elderly. This has led to significant interest on the part of device and combination product providers directed toward the development easier-to-use inhalers. Because they relax smooth muscles in the airways, bronchodilators are an indispensable tool for the treatment of upper respiratory diseases. The market entry of combination drug inhalers that deliver a bronchodilator and a corticosteroid from the same inhaler are providing important options for both clinicians and patients.

Highlights

• Analyzes the market for bronchodilator drugs delivered via oral inhalers
• Assesses inhalation device technology for delivering bronchodilators orally, and evaluates product technology issues and evolving market factors
• Provides detailed assessments of orally inhaled bronchodilator product segments, growth prospects and market potential
• Provides market data and forecasts for orally inhaled bronchodilators to 2022
• Profiles inhaled drug product market participants, their technology, product development activity, and business strategies
• Evaluates the impact of economic, technology, and regulatory factors on inhaled drug companies and their alliance partners

Table Of Contents

Orally Inhaled Bronchodilators to 2022
Executive Summary

Orally Inhaled Corticosteroid Market Overview

The Upper Respiratory Therapeutics Marketspace
Therapeutic Targets for Orally Inhaled Bronchodilators
Competing Drug Treatments
Demand Drivers
Technology Factors
Competitive Landscape

Asthma Market Risks and Opportunities

Global Patient Demographics
Regional Market Drivers
Pediatric Asthma -the Growing Therapeutic Need

Inhaler Technologies for Delivering Bonchodilators

Dry Powder Inhalers
DPI Formulation Technology
Characteristics and Parameters
DPI Excipients and Packaging
Metered Dose Inhalers
MDI Device Selection Criteria
Ease-of-Use Factors
Nebulizers

Inhaled Bronchodilators - Product Analysis, Market Data and Forecasts

Albuterol, Proventil HFA (MDI)
Albuterol, Ventolin HFA (MDI)
Albuterol, ProAir HFA (MDI)
Albuterol, Accuneb (Nebulizer)
Generic Albuterol (Nebulizer)
Albuterol/Ipratropium (Combuvent) Combination Drug Inhaler (MDI)
Albuterol/Ipratropium (Duoneb) Combination Drug Solution (Nebulizer)
Generic Albuterol/Ipratropium Combination Drug Solution (Nebulizer)
Fluticasone/Vilanterol (Breo Ellipta) Combination Drug Inhaler (DPI) Fluticasone/Salmeterol (Advair HFA) Combination Drug Inhaler (MDI)
Fluticasone/Salmeterol (Advair Diskus) Combination Drug Inhaler (DPI)
Formoterol, Foradil (DPI)
Formoterol, Perforomist (Nebulizer)
Formoterol/Mometasone (Dulera) Combination Drug Inhaler (MDI)
Ipratropium, Atrovent HFA (MDI)
Generic Ipratropium (Nebulizer)
Levalbuterol, Xopenex (Nebulizer)
Generic Levalbuterol (Nebulizer)
Levalbuterol, Xopenex HFA( MDI)
Salmeterol, Serevent (DPI)
Tiotropium, Spiriva (DPI)
Tiotropium, Spiriva Respimat (MDI)
Umeclidinium, Incruse Ellipta (DPI)
Umeclidinium/Vilanterol (Anoro) Combination Drug Inhaler (DPI)

Market Factors

Regulatory Issues
Patient Compliance
Prescribing Trends
Healthcare Economics
Regional Market Factors
Connected Devices

Market Sector Company Profiles

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Global Pulmonary Arterial Hypertension (PAH) Therapeutics - Pharmaceuticals

Global Pulmonary Arterial Hypertension (PAH) Therapeutics - Pharmaceuticals

  • $ 4500
  • Industry report
  • January 2017
  • by Global Industry Analysts

This report analyzes the worldwide markets for Pulmonary Arterial Hypertension (PAH) Therapeutics in US$ Million. The Global market is analyzed by the following Drug Class and Brands: Endothelin Recepto ...

Global Human Respiratory Syncytial Virus Drugs Market 2016-2020

Global Human Respiratory Syncytial Virus Drugs Market 2016-2020

  • $ 2500
  • Industry report
  • December 2016
  • by Infiniti Research Limited

About Human Respiratory Syncytial Virus Drugs Respiratory syncytial virus (RSV) is a virus that leads to infections in the lungs and the respiratory tract. It commonly affects most children in the ages ...

Eosinophilic Esophagitis Global Clinical Trials Review, H2, 2016

Eosinophilic Esophagitis Global Clinical Trials Review, H2, 2016

  • $ 2500
  • Industry report
  • November 2016
  • by GlobalData

Eosinophilic Esophagitis Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Eosinophilic Esophagitis Global Clinical Trials Review, H2, 2016" provides an overview of ...

Tygacil -drug Insights, 2017

January 2017 $ 1000

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.